This is an interesting question, which brings another question to mind: would design transfer activities even have begun at phase I clinical studies? I ask because typically for drugs and biologics, transfer to manufacturing is not done during phase I, since low volumes are needed. Phase I studies are run with very small number of patients, which shouldn’t really require manufacturing. If something does not even pass phase I, why would manufacturing even be considered?